Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00150020 · ClinicalTrials.gov registry record · Phase 4
Safety and Tolerability of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients With GI Intolerance
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 728
- Enrollment target
NCT00150020 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 728 participants.
The verdict
NCT00150020, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 728 participants
- Enrollment target
Study Summary
The aim of this study is to evaluate the safety and tolerability of EC-MPS in maintenance renal transplant patients who experience gastrointestinal (GI) intolerance due to adverse events associated with mycophenolate mofetil (MMF) and were converted to EC-MPS.
Interventions
- DRUG Enteric-coated mycophenolate sodium (EC-MPS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 728 participants |
| Start Date | 2004-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00150020
The ClinicalTrials.gov registry entry for NCT00150020 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 728 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enteric-coated mycophenolate sodium (EC-MPS) is the first listed.
NCT00150020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00150020 about?
NCT00150020 is a clinical study titled "Safety and Tolerability of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients With GI Intolerance". The aim of this study is to evaluate the safety and tolerability of EC-MPS in maintenance renal transplant patients who experience gastrointestinal (GI) intolerance due to adverse events associated with mycophenolate mofetil (MMF) and were converted to EC-MPS.
What is the current status of trial NCT00150020?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 728 participants. The study started on 2004-10.
What interventions are being tested in trial NCT00150020?
The interventions under investigation include: Enteric-coated mycophenolate sodium (EC-MPS) (DRUG).
Who is sponsoring clinical trial NCT00150020?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.